Amicus Therapeutics Inc (NASDAQ: FOLD): To Buy Or Not To Buy, That Is The Question

Amicus Therapeutics Inc (FOLD) concluded trading on Thursday at a closing price of $6.29, with 5.22 million shares of worth about $32.82 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.70% during that period and on July 17, 2025 the price saw a gain of about 3.62%. Currently the company’s common shares owned by public are about 307.92M shares, out of which, 297.12M shares are available for trading.

Stock saw a price change of -0.16% in past 5 days and over the past one month there was a price change of 3.97%. Year-to-date (YTD), FOLD shares are showing a performance of -40.83% which decreased to -33.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.51 but also hit the highest price of $12.65 during that period. The average intraday trading volume for Amicus Therapeutics Inc shares is 5.03 million. The stock is currently trading 5.47% above its 20-day simple moving average (SMA20), while that difference is up 3.61% for SMA50 and it goes to -26.67% lower than SMA200.

Amicus Therapeutics Inc (NASDAQ: FOLD) currently have 307.92M outstanding shares and institutions hold larger chunk of about 100.77% of that.

The stock has a current market capitalization of $1.94B and its 3Y-monthly beta is at 0.52. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 2.47 while making debt-to-equity ratio of 2.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FOLD, volatility over the week remained 4.90% while standing at 3.90% over the month.

Analysts are in expectations that Amicus Therapeutics Inc (FOLD) stock would likely to be making an EPS of 0.02 in the current quarter, while forecast for next quarter EPS is 0.11 and it is 0.68 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.03 which is 0.07 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.06 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 51.94% while it is estimated to increase by 398.57% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on July 17, 2025 offering an Overweight rating for the stock and assigned a target price of $108 to it. Coverage by Morgan Stanley stated Amicus Therapeutics Inc (FOLD) stock as an Equal-weight in their note to investors on December 13, 2024, suggesting a price target of $12 for the stock. On September 06, 2024, Jefferies Initiated their recommendations, while on May 30, 2024, Wells Fargo Initiated their ratings for the stock with a price target of $18. Stock get a Buy rating from Guggenheim on May 14, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.